smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from AicurisMunich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from the antibacterial portfolio of Aicuris Anti-infective Cures AG to expand its proprietary pipeline of small-molecule antibiotics. The small molecule disrupts bacterial cell wall synthesis by blocking a step in the biosynthesis pathway of lipopolysaccharide (LPS), a key structural component of the outer membrane in Gram-negative bacteria, via a target that has not been exploited by any approved antibiotics.
